Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01487174 · ClinicalTrials.gov registry record · Phase 3
KD019 Versus Erlotinib in Subjects With Stage IIIB/IV Non Small Cell Lung Cancer With Progression After First- or Second-Line Chemotherapy
A Phase 3 study, sponsored by Kadmon Corporation.
- Terminated
- Registry status
- Phase 3
- Development phase
- 8
- Enrollment target
NCT01487174 is a Phase 3 study that was terminated before completion, run by Kadmon Corporation. The registered enrollment target is 8 participants.
The verdict
NCT01487174, a Phase 3 study, was terminated before completion, sponsored by Kadmon Corporation.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 8 participants
- Enrollment target
Study Summary
This study involves treatment with KD019 or erlotinib in patients with Non-small cell lung cancer (NSCLC) who have progressed after first- or second- line chemotherapy. It is hypothesized that KD019 can prolong survival compared with erlotinib.
Interventions
- DRUG Erlotinib
- DRUG KD019
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2011-12-14 |
| Est. Completion | 2013-07-25 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01487174
The ClinicalTrials.gov registry entry for NCT01487174 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kadmon Corporation, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Erlotinib is the first listed.
NCT01487174 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01487174 about?
NCT01487174 is a clinical study titled "KD019 Versus Erlotinib in Subjects With Stage IIIB/IV Non Small Cell Lung Cancer With Progression After First- or Second-Line Chemotherapy". This study involves treatment with KD019 or erlotinib in patients with Non-small cell lung cancer (NSCLC) who have progressed after first- or second- line chemotherapy. It is hypothesized that KD019 can prolong survival compared with erlotinib.
What is the current status of trial NCT01487174?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 8 participants. The study started on 2011-12-14. Estimated completion is 2013-07-25.
What interventions are being tested in trial NCT01487174?
The interventions under investigation include: Erlotinib (DRUG), KD019 (DRUG).
Who is sponsoring clinical trial NCT01487174?
This trial is sponsored by Kadmon Corporation, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.